Julian Costas joins Clarivate Analytics as the Global Head, Business Development, Licensing and Portfolio Strategy. Julian will be responsible for growing and scaling the company’s existing consulting services globally, in this practice area. Julian has a track record of forging strong business partnerships and in leading diverse cross-functional teams to accelerate innovation in the life sciences industry. He will use his expertise to build customer relationships, drive growth, and provide clients with expert, data-driven advice within the BD&L space. He brings to the table over 25 years of experience from the pharmaceutical and biopharma industry, with expertise in early and late-stage drug value development & assessment, competitive research & analysis, and business development & licensing.
On his new appointment, Julian said, “Our clients are looking for strategic partners that can add value to their analyses and turn data into meaningful and actionable insights. Using the Cortellis suite of intelligence solutions and our expert Consulting Services, we will help clients formulate innovative strategies and gain a commercial advantage by helping them assess the value of their assets, find the right partners, or better understand the commercial and clinical landscape.”
Before that, Julian was Senior Director, Global Market Access at Sanofi, where among other responsibilities, he chaired and led a cross-functional team in medical value assessment of pre-clinical, early and late stage compounds. Additionally, through his work within Sanofi’s Health Economics and Outcomes Research group, he was responsible for building external scientific collaborations with academic institutions, hospitals and major payer groups. Julian was most recently the founder and principal consultant of a consulting practice focused on pharma partnerships, asset value development, valuation modeling and communications.
Prior to Sanofi, Julian was Director, Operations and Client Relations at PPD, a leading contract research organization (CRO), where he led partnerships with more than 30 pharma and biotech companies and supported $50M+ in business. Earlier in his career, Costas held strategic roles at CuraScript and Merck-Medco.
Julian earned his M.B.A from Duke University, The Fuqua School of Business and his B.S. in Pharmacy from Massachusetts College of Pharmacy. He has continued to develop his expertise and earned certification in measurement, design, and analysis methods for health outcomes research from the Harvard School of Public Health.